Literature DB >> 14994756

[Neurooncology].

M Weller1.   

Abstract

The central and peripheral nervous systems give rise to a variety of tumors which differ markedly in their incidence, age preference, and prognosis. The nervous system is also frequently affected by metastatic cancer. The major therapeutic options for tumors of the nervous system include surgical resection, radiotherapy using various strategies of fractionation, total dose, and target volume, and different approaches of chemotherapy such as systemic, intrathecal, and interstitial chemotherapy as well as high-dose chemotherapy with stem cell rescue. An increasing number of therapeutic options in neurooncology are no more merely palliative treatments, but may be curative, indicating that neurooncology is experiencing an era both of controversies regarding previous standards of care and of innovative strategies to combat tumors of the nervous system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14994756     DOI: 10.1007/s00115-003-1645-8

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  11 in total

Review 1.  Brain tumors.

Authors:  L M DeAngelis
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

2.  German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.

Authors:  Ulrich Herrlinger; Martin Schabet; Wolfram Brugger; Rolf-Dieter Kortmann; Wilhelm Küker; Martina Deckert; Corinna Engel; Hans-Jürgen Schmeck-Lindenau; Hans-Günther Mergenthaler; Peter Krauseneck; Christian Benöhr; Christoph Meisner; Otmar D Wiestler; Johannes Dichgans; Lothar Kanz; Michael Bamberg; Michael Weller
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

3.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

Review 4.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

Authors:  L A Stewart
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data.

Authors:  F G Davis; B J McCarthy; S Freels; V Kupelian; M L Bondy
Journal:  Cancer       Date:  1999-01-15       Impact factor: 6.860

6.  Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.

Authors:  Hendrik Pels; Ingo G H Schmidt-Wolf; Axel Glasmacher; Holger Schulz; Andreas Engert; Volker Diehl; Anton Zellner; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Marlies Vogt-Schaden; Gerlinde Egerer; Udo Bode; Carlo Schaller; Martina Deckert; Rolf Fimmers; Christoph Helmstaedter; Aslihan Atasoy; Thomas Klockgether; Uwe Schlegel
Journal:  J Clin Oncol       Date:  2003-11-03       Impact factor: 44.544

Review 7.  Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.

Authors:  Guido Reifenberger; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2003-02       Impact factor: 3.685

8.  Gliomatosis cerebri: molecular pathology and clinical course.

Authors:  Ulrich Herrlinger; Jörg Felsberg; Wilhelm Küker; Antje Bornemann; Ludwig Plasswilm; Christiane B Knobbe; Herwig Strik; Wolfgang Wick; Richard Meyermann; Johannes Dichgans; Michael Bamberg; Guido Reifenberger; Michael Weller
Journal:  Ann Neurol       Date:  2002-10       Impact factor: 10.422

9.  Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.

Authors:  Michael Weller; Bettina Müller; Rainer Koch; Michael Bamberg; Peter Krauseneck
Journal:  J Clin Oncol       Date:  2003-09-01       Impact factor: 44.544

10.  Long-term outcomes after radiosurgery for acoustic neuromas.

Authors:  D Kondziolka; L D Lunsford; M R McLaughlin; J C Flickinger
Journal:  N Engl J Med       Date:  1998-11-12       Impact factor: 91.245

View more
  2 in total

1.  [Relapsing reversible posterior leukoencephalopathy after chemotherapy with cisplatin and 5-fluorouracil].

Authors:  F Paul; O Aktas; F-J Dieste; P Kreitsch; H-P Vogel; F Zipp
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

2.  [Chemotherapy for brain tumors in adult patients].

Authors:  M Weller
Journal:  Nervenarzt       Date:  2008-02       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.